Clinical and laboratory parameters of ITP patients
| Patient . | Sex . | At presentation . | Follow-up . | |||||
|---|---|---|---|---|---|---|---|---|
| Age . | PLT . | IVIg (d) . | PLT (24 h after IVIg) . | Time after . | PLT . | Current condition . | ||
| Group 1 | ||||||||
| P1 | M | 4 | 3 | 2 | 22 | 1 | 250 | Cured |
| P2 | F | 4 | 26 | 2 | 75 | 3 | 271 | Cured |
| P3 | M | 8 | 16 | 5 | 380 | 3 | 341 | Cured |
| P4 | M | 12 | 8 | 5 | 288 | 1 | 257 | Cured |
| P5 | M | 0.7 | 12 | 4 | 24 | 1 | 249 | Cured |
| P6 | F | 10 | 26 | 5 | 218 | 1 | 235 | Cured |
| P7 | F | 4.5 | 21 | 2 | 249 | 1 | 321 | Cured |
| P8 | M | 8 | 10 | 0 | NA | 1 | 235 | Cured |
| P9 | M | 1 | 30 | 0 | NA | 3.5 | 315 | Cured |
| P10 | M | 2 | 5 | 5 | 311 | 3 | 330 | Cured |
| P11 | F | 5.5 | 10 | 2 | 268 | 3 | 341 | Cured |
| P12 | F | 4 | 20 | 5 | 183 | 4 | 201 | Cured |
| Group 2 | ||||||||
| P13 | M | 14 | 28 | 2 | 29 | 2 | 218 | Relapsing ITP |
| P14 | M | 1 | 13 | 4 | 117 | 1 | 216 | Relapsing ITP |
| P15 | M | 8 | 25 | 2 | 66 | 0.5 | 341 | Relapsing ITP |
| 0.6 | 80 | |||||||
| 0.7 | 130 | |||||||
| P16 | F | 10 | 5 | 2 | 106 | 2 | 209 | Relapsing ITP |
| 5 | 216 | |||||||
| P17 | M | 8 | 20 | 1 | 40 | 0.8 | 70 | Chronic ITP |
| P18 | M | 10 | 41 | 1 | 30 | 0.9 | 30 | Chronic ITP |
| 1 | 72 | |||||||
| 1.1 | 35 | |||||||
| Patient . | Sex . | At presentation . | Follow-up . | |||||
|---|---|---|---|---|---|---|---|---|
| Age . | PLT . | IVIg (d) . | PLT (24 h after IVIg) . | Time after . | PLT . | Current condition . | ||
| Group 1 | ||||||||
| P1 | M | 4 | 3 | 2 | 22 | 1 | 250 | Cured |
| P2 | F | 4 | 26 | 2 | 75 | 3 | 271 | Cured |
| P3 | M | 8 | 16 | 5 | 380 | 3 | 341 | Cured |
| P4 | M | 12 | 8 | 5 | 288 | 1 | 257 | Cured |
| P5 | M | 0.7 | 12 | 4 | 24 | 1 | 249 | Cured |
| P6 | F | 10 | 26 | 5 | 218 | 1 | 235 | Cured |
| P7 | F | 4.5 | 21 | 2 | 249 | 1 | 321 | Cured |
| P8 | M | 8 | 10 | 0 | NA | 1 | 235 | Cured |
| P9 | M | 1 | 30 | 0 | NA | 3.5 | 315 | Cured |
| P10 | M | 2 | 5 | 5 | 311 | 3 | 330 | Cured |
| P11 | F | 5.5 | 10 | 2 | 268 | 3 | 341 | Cured |
| P12 | F | 4 | 20 | 5 | 183 | 4 | 201 | Cured |
| Group 2 | ||||||||
| P13 | M | 14 | 28 | 2 | 29 | 2 | 218 | Relapsing ITP |
| P14 | M | 1 | 13 | 4 | 117 | 1 | 216 | Relapsing ITP |
| P15 | M | 8 | 25 | 2 | 66 | 0.5 | 341 | Relapsing ITP |
| 0.6 | 80 | |||||||
| 0.7 | 130 | |||||||
| P16 | F | 10 | 5 | 2 | 106 | 2 | 209 | Relapsing ITP |
| 5 | 216 | |||||||
| P17 | M | 8 | 20 | 1 | 40 | 0.8 | 70 | Chronic ITP |
| P18 | M | 10 | 41 | 1 | 30 | 0.9 | 30 | Chronic ITP |
| 1 | 72 | |||||||
| 1.1 | 35 | |||||||
Group 1 (P1-P12), patients with acute ITP followed by long-term remission, P8 and P9 received no treatment; group 2 (P13-P18), patients P13 to P16 with acute ITP followed by infrequent relapses triggered by viral infections; P17 and P18 had acute ITP followed by frequent episodes occurring within periods of less than 1 month, regardless of infection, requiring continuous monitoring. Only the times when blood samples were given for the present study are shown in the follow-up phase.
PLT indicates number of platelets (× 109/L); IVIg, 2 g/kg body weight (daily dose); NA, not applicable; time after, time in years after the first episode when blood sample was taken for the follow-up study.